IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CANCER-01-03, Project ID 101104421)
Phase:
PHASE3
Details
Lead Sponsor:
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Collaborators:
Charite University, Berlin, Germany Cyprus Institute of Neurology and Genetics Czech Lymphoma Study Group European Leukemia Net Fundacin Instituto de Estudios de Ciencias de la Salud de Castilla y Len Fundacion Para La Investigacion Hospital La Fe German Society for Pediatric Oncology and Hematology GPOH gGmbH Gruppo Italiano Malattie EMatologiche dell'Adulto Hannover Medical School Hospital Vall d'Hebron Lithuanian University of Health Sciences Ospedale Pediatrico Bambin Ges Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V. TIMELEX Toscana Life Sciences Sviluppo s.r.l. University of Bologna